YILING PHARMACEUTICAL(SZ:002603) Shang Hai Zheng Quan Bao·2025-11-12 18:44Core Viewpoint - Shijiazhuang Yiling Pharmaceutical Co., Ltd. has received approval for the listing application of Memantine Hydrochloride, a chemical raw material drug, which is expected to enhance the company's product line and market share in the Alzheimer's treatment sector [1][2]. Group 1: Approval Notification - The approval notification was issued by the National Medical Products Administration for the chemical raw material drug Memantine Hydrochloride, submitted by the company's wholly-owned subsidiary, Hengtai Wanyuan Pharmaceutical Co., Ltd. [1] - The registration number for the drug is Y20240000483, confirming that it meets the requirements for drug registration under Chinese law [1]. Group 2: Drug Overview - Memantine Hydrochloride is a non-competitive NMDA receptor antagonist used to treat moderate to severe Alzheimer's disease, blocking neuronal damage caused by elevated glutamate levels [2]. - According to the 2024 China Alzheimer's Disease Report, there are approximately 16.9 million dementia patients in China, with a prevalence rate of about 1.19% [2]. - The anti-dementia market in China is valued at 1.56 billion yuan, with Memantine being a first-line treatment drug holding a market share of 22% [2]. - The market capacity for Memantine Hydrochloride in China is expected to reach 340 million yuan by 2025, with a year-on-year growth of 11% [2]. Group 3: Impact on the Company - The approval of Memantine Hydrochloride allows the company to sell the drug in the domestic market, enriching its product line and expanding its business scope [3]. - Currently, the approval is not expected to have a significant impact on the company's immediate operating performance [3].